Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:CYTK NASDAQ:ONC NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$88.08-1.7%$94.54$79.52▼$124.00$22.66B1.32860,904 shs837,172 shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsONCBeOne Medicines$270.10-3.5%$301.86$239.25▼$385.22$30.71B0.49224,286 shs324,912 shsRVMDRevolution Medicines$149.23-4.1%$135.34$34.00▼$166.50$33.10B1.42.60 million shs2.14 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.29%-4.12%-6.19%-11.73%-19.39%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%ONCBeOne Medicines+0.33%-3.67%-5.90%-7.04%+8.39%RVMDRevolution Medicines-0.19%+0.69%+5.76%+58.22%+285.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$88.08-1.7%$94.54$79.52▼$124.00$22.66B1.32860,904 shs837,172 shsCYTKCytokinetics$71.48-1.1%$69.97$31.99▼$80.20$9.00B0.422.13 million shs1.61 million shsONCBeOne Medicines$270.10-3.5%$301.86$239.25▼$385.22$30.71B0.49224,286 shs324,912 shsRVMDRevolution Medicines$149.23-4.1%$135.34$34.00▼$166.50$33.10B1.42.60 million shs2.14 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech+1.29%-4.12%-6.19%-11.73%-19.39%CYTKCytokinetics+2.23%-5.88%-6.23%+19.67%+123.05%ONCBeOne Medicines+0.33%-3.67%-5.90%-7.04%+8.39%RVMDRevolution Medicines-0.19%+0.69%+5.76%+58.22%+285.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.74Moderate Buy$129.5647.10% UpsideCYTKCytokinetics 2.86Moderate Buy$99.3038.92% UpsideONCBeOne Medicines 2.80Moderate Buy$390.0044.39% UpsideRVMDRevolution Medicines 3.00Buy$123.72-17.09% DownsideCurrent Analyst Ratings BreakdownLatest CYTK, RVMD, ONC, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/2/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$425.00 ➝ $436.006/2/2026RVMDRevolution Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00 ➝ $182.006/1/2026RVMDRevolution Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$169.00 ➝ $195.006/1/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/1/2026RVMDRevolution Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00 ➝ $195.006/1/2026BNTXBioNTech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026BNTXBioNTech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$117.00 ➝ $135.005/21/2026RVMDRevolution Medicines Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$151.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Perform$96.005/21/2026BNTXBioNTech Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.81B7.94$1.33 per share66.25$96.59 per share0.91CYTKCytokinetics$105.82M84.06N/AN/A($5.39) per share-13.26ONCBeOne Medicines$5.74B5.16$3.78 per share71.38$39.77 per share6.79RVMDRevolution MedicinesN/AN/AN/AN/A$8.44 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)CYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)ONCBeOne Medicines$286.93M$4.4760.4326.05N/A8.94%12.06%6.69%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)Latest CYTK, RVMD, ONC, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74CYTKCytokineticsN/A4.214.21ONCBeOne Medicines0.203.643.27RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%CYTKCytokineticsN/AONCBeOne Medicines48.55%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%CYTKCytokinetics2.60%ONCBeOne Medicines6.19%RVMDRevolution Medicines7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ARVMDRevolution Medicines250212.60 million196.44 millionOptionableCYTK, RVMD, ONC, and BNTX HeadlinesRecent News About These CompaniesWhy Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?June 5 at 12:35 PM | zacks.comAssessing Revolution Medicines (RVMD) Valuation After Positive Daraxonrasib Phase 3 Results At ASCO 2026June 5 at 8:04 AM | finance.yahoo.comRevolution Medicines is up 97% this year: Here are the bull and bear cases for this soaring biotech stockJune 5 at 8:04 AM | msn.comRevolution Medicines, Inc. $RVMD Shares Bought by Westfield Capital Management Co. LPJune 5 at 7:21 AM | marketbeat.comRevolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment - SlideshowJune 3 at 7:11 PM | seekingalpha.comHC Wainwright Issues Negative Forecast for RVMD EarningsJune 3 at 8:05 AM | marketbeat.comWedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)June 2 at 12:45 PM | theglobeandmail.comRoyal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $182.00June 2 at 10:18 AM | marketbeat.comRevolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment TranscriptJune 1, 2026 | seekingalpha.comRVMD Stock Rises on Detailed Results From Pancreatic Cancer StudyJune 1, 2026 | zacks.comRevolution Medicines Jumps 12% As Cancer Drug Data Strengthens CaseJune 1, 2026 | gurufocus.comMUFG Securities EMEA plc Buys New Holdings in Revolution Medicines, Inc. $RVMDJune 1, 2026 | marketbeat.comRVMD stock jumps overnight: New drug heads to FDA after 'unprecedented' 1-year survival win in pancreatic cancerMay 31, 2026 | msn.comRevolution Medicines Reports Breakthrough Phase 3 Results for Daraxonrasib in Metastatic Pancreatic CancerMay 31, 2026 | quiverquant.comQRevolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic CancerMay 31, 2026 | globenewswire.comZweig DiMenna Associates LLC Purchases New Position in Revolution Medicines, Inc. $RVMDMay 30, 2026 | marketbeat.comSBI Okasan Asset Management Co.Ltd. Invests $797,000 in Revolution Medicines, Inc. $RVMDMay 30, 2026 | marketbeat.comJefferies Financial Group Inc. Acquires 1,128,195 Shares of Revolution Medicines, Inc. $RVMDMay 24, 2026 | marketbeat.comCatalyst Funds Management Pty Ltd Purchases 13,400 Shares of Revolution Medicines, Inc. $RVMDMay 24, 2026 | marketbeat.comBernstein initiates coverage of Revolution Medicines (RVMD) with market perform recommendationMay 23, 2026 | msn.comRevolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO PresentationMay 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Uber's Annual Product Showcase Reveals It Is Coming for Airbnb and BookingBy Jessica Mitacek | May 7, 2026Block’s Pivot to Profits and AI Is Turning HeadsBy Peter Frank | May 20, 2026eVTOL Investing: Ditch the Taxi, Buy the BlueprintBy Jeffrey Neal Johnson | May 14, 2026Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckBy Jessica Mitacek | May 8, 2026CYTK, RVMD, ONC, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$88.08 -1.51 (-1.69%) Closing price 04:00 PM EasternExtended Trading$88.18 +0.10 (+0.11%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Cytokinetics NASDAQ:CYTK$71.48 -0.81 (-1.12%) Closing price 04:00 PM EasternExtended Trading$71.32 -0.17 (-0.23%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.BeOne Medicines NASDAQ:ONC$270.10 -9.83 (-3.51%) Closing price 04:00 PM EasternExtended Trading$270.04 -0.06 (-0.02%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Revolution Medicines NASDAQ:RVMD$149.23 -6.46 (-4.15%) Closing price 04:00 PM EasternExtended Trading$148.86 -0.36 (-0.24%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
